dr. ramalingam on the safety of tecemotide
Published 9 years ago • 71 plays • Length 0:34Download video MP4
Download video MP3
Similar videos
-
2:04
dr. ramalingam discusses the utility of tecemotide in nsclc
-
1:05
dr. ramalingam on the activity of osimertinib combinations in nsclc
-
1:45
dr. ramalingam on the use of osimertinib in clinical trial and real-world settings
-
2:47
dr ramalingam on updates in lung cancer following the 2024 asco annual meeting
-
3:13
dr. ramalingam on side effects associated with immunotherapy in lung cancer
-
1:19
dr. ramalingam on emerging combination regimens in nsclc
-
0:56
dr. ramalingam on treatment parameters for osimertinib in lung cancer
-
1:43
dr. ramalingam discusses the results of the phase iii revel study in nsclc
-
2:15
dr. ramalingam on pembrolizumab and chemotherapy in nsclc
-
2:34
dr. ramalingam on flaura findings in egfr-mutant nsclc
-
1:21
dr. suresh s. ramalingam on optimizing immunotherapies in lung cancer
-
1:34
dr. ramalingam on new data for egfr inhibitors for lung cancer
-
6:43
esmo 2018: dr. ramalingam shares insight on lung cancer studies
-
2:22
dr. ramalingam on plasma egfr mutations as a predictor of response in nsclc
-
10:02
gracecast-137_ca-101-_dr. ramalingam: q and a session on clinical trials in oncology
-
2:35
what are dr. ramalingam’s overarching goals for the journal cancer?
-
0:59
dr. ramalingam on next steps with nivolumab/ipilimumab in nsclc
-
1:23
dr. suresh ramalingam explores cytotoxics in lung cancer
-
1:16
suresh ramalingam, md, offers opinion on optimal sequencing of immunotherapy in nsclc